Dr. Reddy’s Laboratories Ltd (REDY)

4,649.90
-21.30(-0.46%)
  • Volume:
    2,377
  • Bid/Ask:
    4,642.05/4,650.60
  • Day's Range:
    4,638.00 - 4,692.95

REDY Overview

Prev. Close
4,671.2
Day's Range
4,638-4,692.95
Revenue
245.88B
Open
4,689.95
52 wk Range
3,996.1-4,987
EPS
271.43
Volume
2,377
Market Cap
772.87B
Dividend (Yield)
40.00
(0.87%)
Average Vol. (3m)
10,291
P/E Ratio
16.69
Beta
0.238
1-Year Change
12.77%
Shares Outstanding
166,121,981
Next Earnings Date
Jul 27, 2023
What is your sentiment on Dr. Reddy’s Labs?
or
Market is currently closed. Voting is open during market hours.

Dr. Reddy’s Laboratories Ltd Company Profile

Dr. Reddy’s Laboratories Ltd Company Profile

Employees
24795
Market
India
  • Type:Equity
  • Market:India
  • ISIN:INE089A01023
  • S/N:DRREDDY

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets; and collaboration with Shanghai Junshi Biosciences Co., Ltd to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyNeutralStrong SellStrong BuyStrong Buy
SummaryStrong BuyNeutralNeutralStrong BuyStrong Buy
  • buy for target 4600 for next Tuesday
    0
    • short sell for 4200
      1
      • buy drreddy target 4550 intraday buyyyyyy
        2
        • sell for a target of 4140
          5
          • Short Sell target 4280
            1
            • q
              0
          • Dr Reddy Intraday Target 4265
            2
            • invest on Vitesse Agro Ltdit will go upto 250 as per expert advice...
              1
              • gape down open hua to put buyer profit book kar le gape up ho e per 4300 ki put buy kare
                0
                • DRREDDY apr 4400 ce buy@55 today plz tell mi hold ir exit
                  1
                  • Hii Dr.redy todaycall option 4500 CE Buy price 92 now Price 65 March ExpPlz suggest Hold ye Exit
                    0
                    • hold dear
                      0